Involvement of serotonin mechanism in methamphetamine-induced chronic pulmonary toxicity in rats

Human and Experimental Toxicology

Volumn 32, Issue 7, 2013, Pages 736-746

  Wang, Y ^a   Liu, M ^b   Wang, H M ^a   Bai, Y ^a   Zhang, X H ^a   Sun, Y X ^a   Wang, H L ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CHINA CRIMINAL POLICE UNIVERSITY   (China)

Author keywords

chronic pulmonary toxicity; inflammation; Methamphetamine; pulmonary arterial hypertension; remodeling; serotonin

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; METHAMPHETAMINE; SEROTONIN; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; CELL INFILTRATION; CHRONIC TOXICITY; CONTROLLED STUDY; DOWN REGULATION; DRUG INDUCED DISEASE; INFLAMMATORY CELL; LONG TERM EXPOSURE; LUNG ARTERY PRESSURE; LUNG PARENCHYMA; LUNG TOXICITY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; RAT; SEROTONIN RELEASE; UPREGULATION; WEIGHT CHANGE; WESTERN BLOTTING;

CHRONIC PULMONARY TOXICITY; INFLAMMATION; METHAMPHETAMINE; PULMONARY ARTERIAL HYPERTENSION; REMODELING; SEROTONIN;

ANIMALS; ARTERIOLES; BLOOD PRESSURE; HEART RATE; LUNG; LUNG DISEASES; MALE; METHAMPHETAMINE; MONOAMINE OXIDASE; PULMONARY ARTERY; RATS; RATS, WISTAR; RNA-BINDING PROTEINS; SEROTONIN; TRYPTOPHAN HYDROXYLASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

RATTUS;

EID: 84879742330     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327112468174     Document Type: Article

References (46)

1. Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of methamphetamine. Clin Toxicol. 2010 ; 48: 675-694
2. Volkow ND, Fowler JS, Wang GJ, Shumay E, Telang F, Thanos PK, et al. Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PLoS One. 2010 ; 5: e15269
3. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009 ; 104: 1085-1099
4. Baumgarten HG, Lachenmayer L. Serotonin neurotoxins past and present. Neurotox Res. 2004 ; 6: 589-614
5. Peter JU, Alenina N, Bader M, Walther DJ. Development of antithrombotic miniribozymes that target peripheral tryptophan hydroxylase. Mol Cell Biochem. 2007 ; 295: 205-215
6. Seo JH, Sung YH, Kim KJ, Shin MS, Lee EK, Kim CJ. Effects of Phellinus linteus administration on serotonin synthesis in the brain and expression of monocarboxylate transporters in the muscle during exhaustive exercise in rats. J Nutr Sci Vitaminol. 2011 ; 57: 95-103
7. Adamsen D, Meili D, Blau N, Thöny B, Ramaekers V. Autism associated with low 5-hydroxyindolacetic acid in CSF and the heterozygous SLC6A4 gene Gly56Ala plus 5-HTTLPR L/L promoter variants. Mol Genet Metab. 2011 ; 102: 368-373
8. Gonçalves J, Baptista S, Martins T, Milhazes N, Borges F, Ribeiro CF, et al. Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur J Neurosci. 2010 ; 31: 315-326
9. Ni W, Geddes TJ, Priestley JR, Szasz T, Kuhn DM, Watts SW. The existence of a local 5-hydroxytryptaminergic system in peripheral arteries. Br J Pharmacol. 2008 ; 154: 663-674
10. Schermuly RT, Ghofrani HA, Wilkins MR, Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol. 2011 ; 8: 443-455
11. Weir EK, Hong Z, Varghese A. The serotonin transporter a vehicle to elucidate pulmonary hypertension?. Circ Res. 2004 ; 94: 1152-1154
12. Wang HL. The serotonin receptor and transporter as potential therapeutic targets for pulmonary hypertension. Curr Opin Investig Drugs. 2004 ; 5: 963-966
13. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000 ; 105: 1555-1562
14. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 ; 54: S20 - S31
15. Wang Y, Han DD, Wang HM, Liu M, Zhang XH, Wang HL. Downregulation of osteopontin is associated with fluoxetine amelioration of monocrotaline-induced pulmonary inflammation and vascular remodeling. Clin Exp Pharmacol Physiol. 2011 ; 38: 365-372
16. Wang Y, Zhang XH, Wang HL. Involvement of BMPR2 in the protective effect of fluoxetine against monocrotaline-induced endothelial apoptosis in rats. Can J Physiol Pharmacol. 2011 ; 89: 345-354
17. Zhai FG, Zhang XH, Wang HL. Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension is relevant to induction of apoptosis and up-regulation of kv1.5 channels in rats. Clin Exp Pharmacol Physiol. 2009 ; 36: 850-856
18. Li XQ, Hong Y, Wang Y, Zhang XH, Wang HL. Sertraline protects against monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol. 2006 ; 33: 1047-1051
19. Li XQ, Wang HM, Yang CG, Zhang XH, Han DD, Wang HL. Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. Acta Pharmacol Sin. 2011 ; 32: 217-222
20. Rothman RB, Baumann MH. Methamphetamine and idiopathic pulmonary arterial hypertension: role of the serotonin transporter. Chest. 2007 ; 132: 1412-1413
21. Wells SM, Buford MC, Braseth SN, Hutchison JD, Holian A. Acute inhalation exposure to vaporized methamphetamine causes lung injury in mice. Inhal Toxicol. 2008 ; 20: 829-838
22. Gotway MB, Marder SR, Hanks DK, Leung JW, Dawn SK, Gean AD, et al. Thoracic complications of illicit drug use: an organ system approach. Radiographics. 2002 ; 22: S119 - S135
23. Hollinger MA. Drug-induced lung toxicity. Int J Toxicol. 1993 ; 12: 31-47
24. Wells SM, Buford MC, Porter VM, Brunel HL, Bunderson-Schelvan M, Nevin AB, et al. Role of the serotonergic system in reduced pulmonary function after exposure to methamphetamine. Am J Respir Cell Mol Biol. 2010 ; 42: 537-544
25. Hervé P, Drouet L, Dosquet C, Launay JM, Simonneau G, Duroux P. Primary pulmonary hypertension in a patient with a familial platelet storage pool disease. Am J Med. 1990 ; 89: 117-120
26. Hervé P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med. 1995 ; 99: 249-254
27. MacLean MR, Herve P. Eddahibi S, and Adnot S. 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol. 2000 ; 131: 161-168
28. Zolkowska D, Rothman RB, Baumann MH. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J Pharmacol Exp Ther. 2006 ; 318: 604-610
29. Esteve JM, Launay JM, Kellermann O, Maroteaux L. Functions of serotonin in hypoxic pulmonary vascular remodeling. Cell Biochem Biophys. 2007 ; 47: 33-43
30. MacLean MR, Dempsie Y. The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol. 2010 ; 661: 309-322
31. Zopf DA, das Neves LA, Nikula KJ, Huang J, Senese PB, Gralinski MR. C-122, a novel antagonist of serotonin receptor 5-HT2B, prevents monocrotaline-induced pulmonary arterial hypertension in rats. Eur J Pharmacol. 2011 ; 670: 195-203
32. Kumer SC, Mockus SM, Rucker PJ, Vrana KE. Amino-terminal analysis of tryptophan hydroxylase: protein kinase phosphorylation occurs at serine-58. J Neurochem. 1997 ; 69: 1738-1745
33. Walther DJ, Peter JU, Bashammakh S, Hörtnagl H, Voits M, Fink H, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science. 2003 ; 299: 76
34. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation. 2006 ; 113: 1857-1864
35. Kitanaka N, Kitanaka J, Takemura M. Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum. Neuroscience. 2005 ; 130: 295-308
36. Richards M, Iijima Y, Kondo H, Shizuno T, Hori H, Arima K, et al. Association study of the vesicular monoamine transporter 1 (VMAT1) gene with schizophrenia in a Japanese population. Behav Brain Funct. 2006 ; 2: 39-44
37. Fleckenstein AE, Volz TJ, Hanson GR. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology. 2009 ; 56: 133-138
38. Narboux-Nême N, Sagné C, Doly S, Diaz SL, Martin CB, Angenard G, et al. Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences. Neuropsychopharmacology. 2011 ; 36: 2538-2550
39. Horton DB, Siripurapu KB, Norrholm SD, Culver JP, Hojahmat M, Beckmann JS, et al. Meso-transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. J Pharmacol Exp Ther. 2011 ; 336: 940-951
40. Rau KS, Birdsall E, Volz TJ, Riordan JA, Baucum AJ II, Adair BP, et al. Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake. J Pharmacol Exp Ther. 2006 ; 318: 676-682
41. Uccella S, Cerutti R, Vigetti D, Furlan D, Oldrini R, Carnevali I, et al. Histidine decarboxylase, DOPA decarboxylase, and vesicular monoamine transporter 2 expression in neuroendocrine tumors: immunohistochemical study and gene expression analysis. J Histochem Cytochem. 2006 ; 54: 863-875
42. Chen NH, Reith ME, Quick MW. Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch. 2004 ; 447: 519-531
43. Rothman RB, Clark RD. Partilla JS, and Baumann MH. (+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters. J Pharmacol Exp Ther. 2003 ; 305: 1191-1199
44. Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol. 2003 ; 479: 23-40
45. Lau T, Schneidt T, Heimann F, Gundelfinger ED, Schloss P.. Somatodendritic serotonin release and re-uptake in mouse embryonic stem cell-derived serotonergic neurons. Neurochem Int. 2010 ; 57: 969-978
46. Fowler JS, Logan J, Wang GJ, Franceschi D, Volkow ND, Telang F, et al. Monoamine oxidase A imaging in peripheral organs in healthy human subjects. Synapse. 2003 ; 49: 178-187